Biogen Prepares More Doubtful Phase III Results For FDA Scrutiny, This Time In ALS
Will Hope To Ride On Coattails Of Amylyx’s Thumbs Up
After the Aduhelm controversy, Biogen has another neurodegenerative disease drug which so far can only show efficacy against surrogate biomarkers – will the FDA be swayed again this time?
